P. Lollar

发表

Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII

D. Lillicrap, P. Zakas, J. Healey, 2020, Frontiers in Immunology.

Anti‐C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model

W. H. Baldwin, S. Meeks, J. Healey, 2018, Journal of thrombosis and haemostasis : JTH.

Structural basis of transcriptional regulation by the HigA antitoxin.

C. Dunham, J. Meisner, Dongxue Wang, 2019 .

Structural basis of transcriptional regulation by the HigA antitoxin

C. Dunham, J. Meisner, Dongxue Wang, 2019, Molecular microbiology.

Expression of Factor VIII by Murine Liver Sinusoidal Endothelial Cells*

E. Waller, J. Healey, P. Lollar, 1999, The Journal of Biological Chemistry.

Association of the factor VIII light chain with von Willebrand factor.

P. Lollar, D. Hill-Eubanks, C. Parker, 1988, The Journal of biological chemistry.

Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation.

A. Thompson, J. Healey, P. Lollar, 1997, Blood.

Characterization of Factor VIII B-Cell Inhibitory Epitopes

P. Lollar, 1999, Thrombosis and Haemostasis.

Subunit structure of thrombin-activated porcine factor VIII.

P. Lollar, C. Parker, C. G. Parker, 1989, Biochemistry.

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII

S. Stoilova-McPhie, J. Healey, P. Lollar, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III.

P. Lollar, W. Owen, 1980, The Journal of clinical investigation.

Activation of porcine factor VIII:C by thrombin and factor Xa.

P. Lollar, D. Fass, P Lollar, 1985, Biochemistry.

A1 Subunit-mediated Regulation of Thrombin-activated Factor VIII A2 Subunit Dissociation*

C. Doering, P. Lollar, E. Parker, 2006, Journal of Biological Chemistry.

Structure and function of Factor VIII.

P. Lollar, 1995, Advances in experimental medicine and biology.

Factor VIII and factor VIIIa.

P. Lollar, D. Fass, P. Fay, 1993, Methods in enzymology.

The association of factor VIII with von Willebrand factor.

P. Lollar, 1991, Mayo Clinic proceedings.

Molecular characterization of commercial porcine factor VIII concentrate.

R. Tracy, P. Lollar, C. Parker, 1988, Blood.

Degradation of coagulation proteins by an enzyme from Malayan pit viper (Akistrodon rhodostoma) venom.

P. Kajenski, P. Lollar, D. Fass, 1987, Biochemistry.

The humoral response to human factor VIII in hemophilia A mice

P. Lollar, E. Parker, W. Church, 2007, Journal of thrombosis and haemostasis : JTH.

Involvement of Thrombin Anion-binding Exosites 1 and 2 in the Activation of Factor V and Factor VIII*

C. Esmon, P. Lollar, 1996, The Journal of Biological Chemistry.

Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator.

P. Lollar, E. Parker, S. Krishnaswamy, 1994, The Journal of biological chemistry.

Porcine recombinant factor VIII (Obizur; OBI‐1; BAX801): product characteristics and preclinical profile

F. Horling, D. Lillicrap, P. Lollar, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

J. Hainfeld, J. Wall, P. Lollar, 1990, The Journal of clinical investigation.

Reconciliation of classical and reacted‐site probability approaches to allowance for ligand multivalence in binding studies

D. Winzor, P. Lollar, 2014, Journal of molecular recognition : JMR.

High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.

C. Hausl, C. Doering, H. Schwarz, 2005, Blood.

Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor Xdes-143-191.

P. Lollar, E. J. Duffy, 1992, The Journal of biological chemistry.

High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

K. Lewis, S. Meeks, J. Healey, 2014, Blood.

Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

C. Kempton, C. Doering, S. Meeks, 2011, Blood.

The diversity of the immune response to the A2 domain of human factor VIII.

S. Meeks, J. Healey, P. Lollar, 2013, Blood.

Isolation and characterization of native adult osteonectin.

K. Mann, B. Riggs, P. Lollar, 1985, The Journal of biological chemistry.

Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

W. H. Baldwin, S. Stowell, S. Meeks, 2017, Blood.

Fill 'er up? Fill what up?

P. Lollar, 2016, Blood.

Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.

P. Lollar, D. Hill-Eubanks, C. G. Parker, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Prostacyclin release from cultured and ex vivo bovine vascular endothelium. Studies with thrombin, arachidonic acid, and ionophore A23187.

C. Jafvert, P. Lollar, J. Hoak, 1981, Laboratory investigation; a journal of technical methods and pathology.

Optimal treatment regimens for patients with bleeding disorders

Blanchette, Christine A. Lee, G. Mariani, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity*

W. Bode, H. Brandstetter, Jianping Jin, 1998, The Journal of Biological Chemistry.

SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa

H. Spencer, C. Doering, P. Lollar, 2022, Blood advances.

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.

S. Meeks, J. Healey, P. Lollar, 2008, Blood.

Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.

S. Meeks, J. Healey, P. Lollar, 2007, Blood.

Analysis of Factor VIII Inhibitors Using Hybrid Human/Porcine Factor VIII

P. Lollar, 1997, Thrombosis and Haemostasis.

Subunit Flexibility of Multimeric von Willebrand Factor/Factor VIII Complexes

P. Lollar, E. Parker, S. Haberichter, 2022, ACS omega.

Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor

P. Lollar, Pete Lollar, 2005, Journal of thrombosis and haemostasis : JTH.

High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

W. H. Baldwin, C. Königs, Renhao Li, 2016, Blood.

Anti‐factor VIII antibodies in brothers with haemophilia A share similar characteristics

C. Königs, J. Astermark, S. Donfield, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Endothelial Receptor-Mediated Clearance of Thrombin: Comparison with two active Site-Inhibited Derivatives.

P. Lollar, W. Owen, 1979 .

Subunit structure and function of porcine factor Xa-activated factor VIII.

P. Lollar, E. Parker, J. Pohl, 1997, Biochemistry.

The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain

H. Spencer, C. Doering, I. Smith, 2020, Journal of thrombosis and haemostasis : JTH.

hemophilia A with factor VIII inhibitors High-dose factor VIII inhibits factor VIII-specific memory B cells in

C. Hausl, C. Doering, H. Schwarz, 2012 .

Short title: Anti-factor VIII C2 domain antibody epitopes

S. Meeks, J. Healey, P. Lollar, 2007 .

hemophilia A with factor VIII inhibitors specific memory B cells in − High-dose factor VIII inhibits factor VIII

C. Hausl, C. Doering, H. Schwarz, 2005 .

Factor VIII inhibitors.

J. Healey, P. Lollar, E. Parker, 2001, Advances in experimental medicine and biology.

Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII (*)

J. Healey, P. Lollar, I. Lubin, 1995, The Journal of Biological Chemistry.

Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

C. Königs, J. Healey, P. Lollar, 2017, Blood.

Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX

P. Lollar, 2004, Journal of thrombosis and haemostasis : JTH.

High stakes immunology.

P. Lollar, 2011, Blood.

Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII

P. Lollar, R. T. Barrow, R. T. BARROW, 2006, Journal of thrombosis and haemostasis : JTH.

Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope.

J. Healey, P. Lollar, E. Parker, 2004, Blood.

Identification of Porcine Coagulation Factor VIII Domains Responsible for High Level Expression via Enhanced Secretion*

C. Doering, J. Healey, P. Lollar, 2004, Journal of Biological Chemistry.

High Level Expression of Recombinant Porcine Coagulation Factor VIII*

C. Doering, J. Healey, P. Lollar, 2002, The Journal of Biological Chemistry.

Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.

J. Healey, P. Lollar, D. Scandella, 2000, Blood.

Epitope mapping via selection of anti-FVIII antibody-specific phage-presented peptide ligands that mimic the antibody binding sites.

C. Königs, J. Healey, P. Lollar, 2014, Thrombosis and haemostasis.

Decreasing the Humoral Response to Factor VIII By Targeted Deletion of Factor VIII - Specific B Cells

W. H. Baldwin, S. Meeks, J. Healey, 2014 .

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor

H. Spencer, C. Doering, P. Lollar, 2021, Frontiers in Immunology.

Structure of Blood Coagulation Factor VIII in Complex with Anti-C2 Domain Inhibitory Antibody

H. Spencer, C. Doering, P. Lollar, 2021 .

The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice

J. Healey, P. Lollar, E. Parker, 2009, Thrombosis and Haemostasis.

Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.

J. Healey, P. Lollar, M. Shima, 1998, Blood.

Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.

P. Lollar, E. Parker, 1991, Journal of Biological Chemistry.

X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.

H Brandstetter, R. Huber, W. Bode, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone.

P. Lollar, D. Fass, P Lollar, 1984, Archives of biochemistry and biophysics.

Binding of thrombin to cultured human endothelial cells. Nonequilibrium aspects.

P. Lollar, J. Hoak, W. Owen, 1980, Journal of Biological Chemistry.

THROMBOSIS AND HEMOSTASIS High-resolution mapping of epitopes on the C 2 domain of factor VIII by analysis of point mutants using surface plasmon resonance

K. Lewis, S. Meeks, J. Healey, 2014 .

Comparative immunogenicity of recombinant B domain‐deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII

P. Lollar, E. Parker, R. T. Barrow, 2004, Journal of thrombosis and haemostasis : JTH.

Molecular Characterization of the Immune Response to Factor VIII

P. Lollar, 2002, Vox sanguinis.

Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

J. E. Curtis, P. Lollar, E. Parker, 1994, The Journal of clinical investigation.

Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.

Shannon L Meeks, S. Meeks, J. Healey, 2013, Blood.

Characterization and Solution Structure of the Factor VIII C2 Domain in a Ternary Complex with Classical and Non-classical Inhibitor Antibodies*

S. Meeks, J. Healey, P. Lollar, 2013, The Journal of Biological Chemistry.

The cDNA and derived amino acid sequence of porcine factor VIII.

J. Healey, P. Lollar, I. Lubin, 1996, Blood.

Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.

P. Lollar, E. Parker, A. Johnson, 1992, The Journal of biological chemistry.

Mechanism of the Immune Response to Human Factor VIII in Murine Hemophilia A

H. Wu, P. Lollar, E. Parker, 2001, Thrombosis and Haemostasis.

Expression and Characterization of Recombinant Murine Factor VIII

C. Doering, J. Healey, P. Lollar, 2002, Thrombosis and Haemostasis.

Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.

Eli J. Fine, H. Spencer, C. Doering, 2018, Human gene therapy.

hemophilia A mice by mutagenesis of the A2 domain B-cell epitope Reduction of the inhibitory antibody response to human factor VIII in

J. Healey, P. Lollar, E. Parker, 2010 .

A quantitative measure of the efficacy of factor VIII in hemophilia A mice

P. Lollar, E. Parker, 2003, Thrombosis and Haemostasis.

Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.

H. Spencer, C. Doering, B. Gangadharan, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.

Shannon L Meeks, B. Gangadharan, S. Meeks, 2012, Blood.

Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene

W. H. Baldwin, M. Lenardo, P. Jiang, 2016, Journal of thrombosis and haemostasis : JTH.

Antigenicity of putative phospholipid membrane-binding residues in factor VIII.

J. Healey, P. Lollar, J. Saint-Remy, 2001, Blood.

Hemophilia and immunology at the crossroads

P. Lollar, 2006, Journal of thrombosis and haemostasis : JTH.

Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII.

T. Ortel, J. Voorberg, N. Bovenschen, 2002, Blood.

Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis*

J. Healey, P. Lollar, I. Lubin, 1997, The Journal of Biological Chemistry.

Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII.

P. Lollar, L. Hoyer, J. Qian, 1995, Blood.

Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.

Liming Chang, R. Hebbel, J. Healey, 2002, Blood.

Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.

P. Lollar, E. Parker, 2007, Biochemistry.

Mechanism-based isocoumarin inhibitors for blood coagulation serine proteases. Effect of the 7-substituent in 7-amino-4-chloro-3-(isothioureidoalkoxy)isocoumarins on inhibitory and anticoagulant potency.

F. L. Suddath, J. Kerrigan, J. Powers, 1994, Journal of medicinal chemistry.

Evidence that the effects of thrombin on arachidonate metabolism in cultured human endothelial cells are not mediated by a high affinity receptor.

P. Lollar, W. Owen, 1980, The Journal of biological chemistry.

Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure.

C. Doering, P. Lollar, C. Josephson, 2002, Blood.

ACTIVE‐SITE‐DEPENDENT, THROMBIN‐INDUCED RELEASE OF ADENINE NUCLEOTIDES FROM CULTURED HUMAN ENDOTHELIAL CELLS *

P. Lollar, W. Owen, 1981, Annals of the New York Academy of Sciences.

Delimiting the autoinhibitory module of von Willebrand factor

E. Ortlund, J. K. Colucci, E. R. Legan, 2018, Journal of thrombosis and haemostasis : JTH.

A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor

J. Healey, P. Lollar, A. Syed, 2017, Journal of thrombosis and haemostasis : JTH.

The factor VIII assay problem: neither rhyme nor reason

P. Lollar, 2003, Journal of thrombosis and haemostasis : JTH.

Elimination of a major inhibitor epitope in factor VIII.

M. Runge, J. Healey, P. Lollar, 1994, The Journal of biological chemistry.

VIII molecules antibody plasmas using multiply-substituted hybrid human/porcine factor Reduction of the antigenicity of factor VIII toward complex inhibitory

J. Healey, P. Lollar, D. Scandella, 2013 .

The cDNA and Derived Amino Acid Sequence of Porcine Factor VI 11 By

J. Healey, P. Lollar, I. Lubin, 2002 .

Decreased factor VIII levels during acetaminophen-induced murine fulminant hepatic failure.

C. Doering, P. Lollar, E. Parker, 2003, Blood.

Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid.

P. Lollar, D. Fass, G. Knutson, 1984, Blood.

CASE REPORT Massive Fatal Pulmonary Emboli with Fibrinolytic Therapy

P. Lollar, J. Hoak, J. Goldsmith, 2005 .

Massive fatal pulmonary emboli with fibrinolytic therapy.

P. Lollar, J. Hoak, J. Goldsmith, 1981, Circulation.

Desialylation of O‐glycans activates von Willebrand factor by destabilizing its autoinhibitory module

P. Azadi, Renhao Li, E. R. Legan, 2021, Journal of thrombosis and haemostasis : JTH.

Isolation and characterization of thrombin-activated human factor VIII.

J. E. Curtis, P. Lollar, E. Parker, 1994, The Journal of biological chemistry.

Reaction of antithrombin III with thrombin bound to the vascular endothelium. Analysis in a recirculating perfused rabbit heart preparation.

P. Lollar, W. Owen, S. Macintosh, 1984, The Journal of biological chemistry.

Involvement of the contact phase and intrinsic pathway in herpes simplex virus‐initiated plasma coagulation

P. Lollar, E. Pryzdial, M. R. Sutherland, 2010, Journal of thrombosis and haemostasis : JTH.

Non‐classical anti‐factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model

S. Meeks, J. Healey, P. Lollar, 2008, Journal of thrombosis and haemostasis : JTH.

The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study.

P. Lollar, A. Johnson, V. Mutucumarana, 1992, The Journal of biological chemistry.

SAXS analysis of intrinsic tenase complex bound to lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa

H. Spencer, C. Doering, P. Lollar, 2021, bioRxiv.

von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain.

P. Lollar, P Lollar, D C Hill-Eubanks, 1990, The Journal of biological chemistry.

Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation

J. Healey, P. Lollar, E. Parker, 2018, Journal of thrombosis and haemostasis : JTH.

Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody

Y. Goldgur, E. Sundberg, D. Oren, 2023, Nature communications.

Mechanism of glycoform specificity and protection against antibody dependent enhancement by an anti-afucosylated IgG nanobody

Y. Goldgur, E. Sundberg, D. Oren, 2023, bioRxiv.

Coagulant properties of hybrid human/porcine factor VIII molecules.

P. Lollar, E. Parker, P. Fay, 1992, The Journal of biological chemistry.

pH-dependent denaturation of thrombin-activated porcine factor VIII.

P. Lollar, C. G. Parker, C. G. Parker, 1990, The Journal of biological chemistry.

Conformation of the von Willebrand factor/factor VIII complex in quasi-static flow

P. Lollar, E. Parker, 2021, The Journal of biological chemistry.

Differential Immunodominance of Human and Porcine Factor VIII in Hemophilia A Mice.

J. Healey, P. Lollar, E. Parker, 2004 .

Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens

P. Berman, J. Healey, P. Lollar, 2020, PloS one.

Stoichiometry of the porcine factor VIII-von Willebrand factor association.

P. Lollar, C. G. Parker, 1987, The Journal of biological chemistry.

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor

O. Davulcu, C. Doering, P. Lollar, 2023, Blood.

Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex.

J. Healey, P. Lollar, R. Barrow, 1994, The Journal of biological chemistry.

Structure of Blood Coagulation Factor VIII in Complex with an Anti-C1 Domain Pathogenic Antibody Inhibitor.

H. Spencer, C. Doering, P. Lollar, 2021, Blood.

Crystal Structure of the Antihaemophilic Clotting Factor IXa

R. Huber, W. Bode, H. Brandstetter, 1996 .

Reconciliation of classical and reacted‐site probability approaches to allowance for ligand multivalence in binding studies

D. Winzor, P. Lollar, 2014, Journal of molecular recognition : JMR.

High-Resolution Mapping of B-Cell Epitopes on the Factor VIII C2 Domain Using Surface Plasmon Resonance

K. Lewis, S. Meeks, J. Healey, 2011 .

INTERACTION OF THROMBIN WITH THE VASCULAR ENDOTHELIUM IN A RECIRCULATING LANGENDORFF RABBIT HEART PREPARATION *

P. Lollar, W. Owen, S. M, 1982, Annals of the New York Academy of Sciences.